Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

Program Description

Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness with diverse presentations across age groups and a significant impact on patients’ quality of life. Traditional treatment is guided by antibody confirmation and tailored to disease severity using acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, or intravenous immunoglobulin (IVIg)/plasma exchange, while considering patient-specific factors. While current therapies for MG have significantly reduced mortality, many patients continue to face challenges such as incomplete remission, treatment-limiting adverse effects from steroids and immunosuppressants, and logistical barriers with IVIg or plasmapheresis that require reliable venous access. Newly approved biologics, including FcRn inhibitors, offer a novel route of administration with the potential for sustained efficacy, improved tolerability, and greater patient satisfaction compared with conventional regimens. It is essential for specialty pharmacists to be educated on new therapies for gMG because they play a central role in identifying appropriate patients, navigating access barriers, and ensuring safe, effective, and individualized treatment. This webinar will focus on the roles and responsibilities of specialty pharmacists in medication management and multidisciplinary collaboration in gMG. Strategies for integrating these emerging FcRn therapies into clinical practice and providing effective education to improve adherence to, access to, and affordability of new targeted therapies will be discussed.

Target audience: Specialty Pharmacist

Type of activity: Application
Release date: October 31, 2025
Expiration date: October 31, 2026

Time to complete activity: 1.0 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Determine the role of FcRn in the pathogenesis of generalized myasthenia gravis (gMG) and the mechanism of action of FcRn inhibitors
2. Analyze clinical trial data supporting the use of FcRn therapies for patients with anti-AChR antibody-positive gMG
3. Identify appropriate candidates for FcRn therapy based on clinical and biomarker criteria
4. Apply pharmacist-driven strategies to overcome access barriers and facilitate timely initiation of FcRn-targeted treatment

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-359-H01-P. The activity is available for CE credit through October 31, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Erica Marini, PharmD, MS, BCPS

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms